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1. Introduction 
Malignant gliomas are the most common primary brain tumor, with median survival of less 
than 15 months from the time of diagnosis. (Stupp R, et al., 2005) Most malignant tumors 
contain a small subpopulation of cells that are highly tumorigenic and share features with 
normal stem cells, including the ability for extensive self-renewal and to differentiate into 
multiple lineages. Many tumors, including glioblastomas, are activated by these cancer stem 
cells, making them resistant to conventional therapies such as radiation and 
chemotherapies. In addition, these cancer stem cells adopt the signaling pathways of normal 
neural stem and progenitor cells, thereby playing a critical and complex role in 
tumorigenesis, allowing the tumor to rapidly progress, proliferate, and metastasize. Thus, 
the pathologic pathways directed by these cancer stem cells make gliomas hard to treat and 
regulate.  Therefore, in order to understand gliomas as well as the cancer treatment-related 
neurotoxicity on a cellular level, it is crucial to be familiar with the concept of glioma stem 
cells and their lineage relationships with the central nervous system. Furthermore, to 
effectively target these cancer stem cells, an understanding of the molecular profiling of 
well-characterized cancer cell populations is necessary to identify novel biomarkers that will 
provide the foundation to track their targeted pathways. This will help evaluate and 
personalize treatment options to help advance our knowledge in the biology of glioma and 
translate these concepts into the clinical arena. Thus, this chapter will focus on the current 
understanding on progenitor cells and neural stem cells and highlight important findings 
regarding the identification and characterization of glioma stem cells, and the development 
of novel-stem-cell-based treatment strategies for brain tumors. 
2. Glioma and stem cells 
Malignant gliomas, aside from being the most common brain tumor, are very challenging to 
treat with median survival times of less than 15 months from time of diagnosis (Stupp R, et 
al., 2005). Many of the malignant gliomas, especially glioblastomas, display aberrant genetic 
abnormalities that contribute to their pathologic cellular and morphological heterogeneity 
(Tabatabai & Weller, 2011). This tumor heterogeneity thus poses a critical obstacle in 
treating malignant gliomas because different cell populations within the tumor tissues 
respond differently to treatments such as conventional chemotherapy and radiation 
(Tabatabai & Weller, 2011; Bao, et al., 2006; Dietrich et al., 2008). In addition, the tumor’s 
tendency to aggressively infiltrate into the surrounding brain parenchyma, therefore 
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preventing a complete surgical tumor resection, hinders the treatment of gliomas and results 
in fatal tumor recurrences. (Bao, et al., 2006; Cheng L, et al., 2011; Dietrich et al., 2008).  
 
 
Fig. 1. Resistance mechanisms in glioma cells  
Normal neural stem cells self-renew and give rise to multipotential progenitor cells that 
form neurons, oligodendroglia, and astrocytes. Glioma stem cells arise from the 
transformation of either neural stem cells or progenitor cells (red) or, less likely, from 
differentiation of a oligodendrocytes or astrocytes (red arrows) and lead to malignant 
gliomas. Glioma stem cells are relatively resistant to standard treatments such as radiation 
and chemotherapy and lead to regrowth of the tumor after treatment. Therapies directed at 
stem cells can deplete these cells and potentially lead to more durable tumor regression 
(blue). 
To complicate the matters further, early and effective detection of these cancers are 
extremely difficult, resulting in a poor prognosis for the patients diagnosed with malignant 
gliomas (Huang Z et al., 2010). Then, these difficulties collectively warrant for reevaluation 
of current treatments in order to achieve optimal efficacy, prolong the survival, and improve 
and maximize the quality of life for the patients.   
Recent studies suggest that in order to understand the pathologic nature of malignant 
gliomas, it is crucial to acknowledge the role of cancer stem cells that are involved in the 
processes of tumor initiation, tumor progression, angiogenesis and resistance to therapy 
(Huang Z et al., 2010). In a study done by Park et al., even though the correlational 
relationship between gliomas stem cells and massive tumor is not clear, it is possible that the 
stem cells contribute to the tumor recurrence after the initial, conventional therapies (Park & 
Rich, 2009). These cancer stem cells are also known as the tumor-initiating or propagating 
cells because they display and share some important characteristics with normal stem cells, 
including self-renewal, multi-lineage differentiation, and maintained proliferation (Huang Z 
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et al., 2010; Rosen and Jordan 2009; Park & Rich, 2009; Heddleston et al., 2010). Also similar 
to neural stem cells, cancer stem cells appear to be organized and depend on vascular and 
nonvascular elements (Dietrich, et al., 2008, Calabrese,et al.,2007). Although the exact origin 
of the gliomas stem cells is still controversial, there seems to be a consensus that these cancer 
stem cells arise from genetic and epigenetic changes in neural stem and progenitor cells after 
many mutations or epigenetic transcription (Huang Z et al., 2010). 
Therefore, exploring the signaling pathways and molecular mechanisms that drive these 
tumor-initiating cells in malignant gliomas is necessary to identify and provide promising 
novel treatment strategies. In order to understand the exact mechanisms that govern cancer 
stem cells’ role in tumor angiogenesis and extensive proliferation, a careful insight into the 
cancer stem cell signaling mechanisms warrants further analysis and investigation to 
optimize brain tumor treatment. 
3. Glioma stem cell signaling 
The main factor that contributes to the cancer cells’ extensive proliferation within their 
perivascular niche is the cell-extrinsic and cell-intrinsic signals. Therapeutic targeting of 
these signals within their niche, along with the tumor-associated vasculature may 
significantly interfere with glioma cancer stem cell growth (Park & Rich, 2009; Dietrich et al., 
2010).  In clinical studies done by Kreisl et al., and Vredenburgh et al., the administration of 
bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) 
demonstrated a clinical effectiveness in achieving therapeutic response (Kreisl et al., 2009; 
Vredenburgh et al., 2007). As evident by this and other ongoing studies, providing therapies 
that target these glioma stem cell signaling pathways not only provide effective treatment 
by directly targeting these stem cells but also gives us valuable insights into the 
pharmacodynamics of cancer stem cells’ dependence on the perivascular niche for survival, 
growth, and proliferation (Park & Rich, 2009). Therefore, the following major signal 
transduction pathway cascades will be extensively reviewed to provide highly 
discriminating targets and tumor biomarkers of therapeutic response: epidermal growth 
factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), RAS/Raf/MAPK & AKT/PI3K pathways, Sonic hedgehog (Shh), and PTEN. 
3.1 Epidermal growth factor signaling 
Epidermal growth factor related signaling has probably been the most extensively studied 
pathway in malignant gliomas. Epidermal growth factor receptor (EGFR) is a tyrosine 
kinase that is activated upon ligand binding which induces receptor dimerization. EGFR 
signaling is involved in many aspects of cellular events including corticogenesis, neural cell 
survival, proliferation, differentiation, and migration (Ayuso-Sacido et al., 2009; Zhu G et al., 
2000). The overexpression of EGFR plays a significant role in GBM and other malignant 
gliomas’ pathologic progression (Ayuso-Sacido et al., 2009). In addition, EGFR is important 
in neural cell fate and astrocyte differentiation. EGFR expression is often mutated in more 
than 50% of glioblastomas, with EGFRvIII, a truncated extracellular domain within EGFR 
that transform into an active ligand-independent kinase, being the most common mutant 
encountered in gliomas and is responsible for enhanced tumorigenic behavior and genetic 
instability (Ayuso-Sacido et al., 2009; Frederick et al., 2000, Liu L et al., 2005; Rasheed BK et 
al., 1999; Ekstrand, 1991; Wong, 1992; Collins, 1993; Mellinghoff, 2005; Aldape, 2004; 
Pelloski, 2007; Huang, 2007; Li, 2009).  
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In experimental studies looking at the role of EGFR and the expression of EGFR vIII, the 
expression of EGFRvIII in the glial lineage in mouse models were significantly similar to 
human gliomas and in addition, these lesions were mainly occurring within the progenitor 
cells (Ayuso-Sacido et al., 2009; Dai C et al., 2001; Halatsch ME et al., 2000; Holland EC et al., 
2004; Laywell ED et al., 2000). The critical importance of EGF-mediated signaling in gliomas 
is that these signaling have been shown to contribute to both normal stem cell behavior and 
to pathologic gliomagenesis. Activated EGFR signaling pathway induce normal stem cells to 
display characteristics that are seen in glioma stem cells including increased proliferation, 
migration and survival (Ayuso-Sacido et al., 2000). Consequently, it has been suggested that 
interference with EGFR and EGFRvIII signaling may offer an attractive strategy for selective 
glioma therapy (Huang, 2007; Shir, 2006; Zhu, 2009). 
Selective small-molecules designed to inhibit EGF/EGFR signaling were among the first 
targeted molecular therapies used in glioblastoma patients. One of the drugs that is being 
investigated to treat gliomas is gefitinib (Iressa®), a selective EGFR inhibitor. However, in 
preclinical studies using gefitinib to observe its activity revealed that the drug showed 
selective efficacy in tumors that have mutations in exons 19 and 21 of the amplified 
HER1/EGFR-TK domain (Halatsch ME et al., 2006; Lynch T et al., 2004; Paez J et al., 2004). 
This result might be the reason why gefitinib is ineffective in treating malignant gliomas, 
including GBM, because these mutations have not been found in gliomas (Marie Y et al., 
2005; Halatsch ME et al., 2006). In addition, preclinical data showed that gefitinib has  very 
low or no activity against tumors that express EGFRvIII (Heimberger AB et al., 2002). 
Clinical data shows that gefitinib for glioma patients are generally well tolerated with few, 
minor side effects. However, when compared with historical data, event-free/progression-
free survival and median overall survival were same and gefitinib failed to produce 
effective objective response (Wong et al., 1999; Rich,2004).  
Erlotinib (Tarceva®, OSI-774) is another inhibitor of EGFR and the constitutively active 
mutant EGFRvIII.  In pre-clinical studies, erlotinib suppressed GBM cell lines’ anchorage-
independent growth, suggesting that erlotinib may prevent or even delay GBM recurrence 
following surgical resection (Halatsch ME et al., 2006). For erlotinib, phase I/II clinical study 
data indicate that it was well tolerated and findings from phase I trials supported the data 
from phase II trials in terms of response rates and its antitumor effects (Brewer et al., 2005). 
The results of a large multicenter Phase II trial, in which patients with progressive 
glioblastoma were randomly assigned to erlotinib, or conventional chemotherapy with 
either temozolomide or carmustine (BCNU), revealed that erlotinib had insufficient activity 
when used as monotherapy (van den Bent, 2009).  
Taken together, monotherapy with anti-EGFR agents such as gefitinib and erlotinib, thus 
far, have not demonstrated significant activity in patients with malignant glioma. However, 
recent studies suggest that combining the anti-EGFR agents with inhibitors of other 
molecular target may provide more effective approach in treating malignant gliomas. For 
example, dual-kinase inhibition of EGFR and ErbB-2 (e.g., lapatinib) (Spector, 2005; 
Giannopoulou, 2009), or EGFR and VEGF recepetor (VEGFR; e.g., AEE788; 
Zactima®/vandetanib/ZD6474) (Traxler, 2004; Goudar, 2005; Sandstrom, 2008). Since the 
stem cell biology suggests that glioma stem cells display a close resemblance to the normal 
neural cells, our current knowledge of normal stem cell can help analyze and deregulate the 
pathway of the cancer stem cells to provide promising, therapeutic results. 
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3.2 Platelet-derived growth factor signaling 
Platelet-derived growth factor (PDGF) and its associated receptors play fundamental roles 
in the developing and adult brain. (Yeh,1993) Studies from in vivo animal models show that 
there is a correlational relationship between the abnormal PDGF signaling and glioma 
formation (Calzolari & Malatesta, 2009). Often times in gliomas, PDGF ligands are 
overexpressed along with their PDGFRα receptors. Hence these amplification-dependent 
receptors or the ligands give rise to aberrant, overactive PDGF signaling pathway (Calzolari 
& Malatesta, 2009). In the adult brain, PDGFR-a expression is found in the lateral 
subventricular zone, whereas PDGF is abundantly expressed by neurons and astrocytes 
(Oumesmar, 1997). 
Also in animal model studies increased PDGF signaling blocked neuroblast generation and 
enhanced neural stem cell proliferation in the subventricular zone with formation of glioma-
like hyperplasias (Jackson, 2006). Moreover, the inhibition of PDGF-mediated signaling 
decreases glioma cell proliferation both in vitro and in vivo (Lokker, 2002), supporting the 
role of both autocrine and paracrine mechanisms in glioma biology. The fact that many of 
the malignant gliomas display altered and overactive PDGF pathway suggest that this 
signaling axis plays an important role in gliomagenesis. Also it seems likely that PDGF 
signaling is involved and is crucial in tumor proliferation and survival by stimulating 
growth and supplying nutrients to underlying tumor cells (di Tomaso E et al., 2009).   
Imatinibmesylate (Gleevec®) is a small-molecule, oral inhibitor of multiple tyrosine kinases 
including PDGFR α and β, c-KIT and the BCR-ABL onco-protein (Morris & Abrey 2010). In a 
phase I/II study done by Wen et al., Imatinib in a monotherapy setting showed 
disappointing results. Of the 105 patients who were enrolled, 68% of the patients had very 
low imatinib in their plasma when taking the drug with enzyme inducing anti-epileptic 
drugs (EIAEDs). This is a serious problem because most glioma patients are on anti-seizure 
medications, regardless of the treatments that they are receiving. In addition, to the low 
pharmacokinetic data, imatinib also induced intratumoral hemorrhages and showed no 
therapeutic responses to patients with anaplastic gliomas (Morris & Abrey 2010; Wen PY et 
al., 2006). Another phase II showed disappointing results with having 6-moth PFS rate of 
16% in GBM, 9% in astrocytomas, and 4.0% in oligodendrogliomas (Raymond et al., 2008). 
In a combination therapy regimen, administering imatinib with temozolomide found to be 
tolerable in many patients. However in several clinical studies observing a combined 
treatment of imatinib with hydroxyurea, a ribonucleoside diphosphate reductase inhibitor, 
showed disappointing results (Reardon DA et al., 2005 & 2008).While other PDGFR 
pathway inhibitors are currently under clinical investigation (Roberts, 2005), dual kinase 
inhibitors, or combinational therapies with conventional cytotoxic agents are also 
developing including PDGFR and VEGFR dual inhibitors such as PTK787 (vatalanib), 
sorafenib (Nexavar), sunitinib, AEE788, AZD2171 (cediranib), TKI258, OSI-930 and 
pazopanib. Also, there are studies observing the efficacy of nilotinib (Tasigna®), which is an 
oral drug that has greater potency and selectivity for BCR-ABL than imatinib (Saglio G et al., 
2010).   
3.3 Vascular endothelial growth factor signaling 
Antiangiogenic treatments examining VEGF and its associated signaling cascade have been 
an integral part in modern cancer therapy by targeting extensive tumor vasculatures of the 
malignant gliomas (Wick et al., 2011). Both endothelial cells and glioma cells may express 
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and upregulate VEGF and its receptors, resulting in both paracrine and autocrine loops that 
drive endothelial cell proliferation, tumor invasion, migration and permeability. 
(Ferrara, 2003; Millauer, 1994) Also, there are circumstantial evidence that elevated VEGF 
expression in gliomas is associated with the degree of malignancy of the tumor and overall 
tumor prognosis (Schmidt, 1999; Leon, 1996). 
Glioma stem cells appear to be directly involved in this process by stimulating tumor 
angiogenesis through production of pro- angiogenic factors, such as VEGF (Bao, 2006). In 
many gliomas, especially in glioblastomas, the neural stem cells and their endothelial 
compartment closely interact with the vascular niche and by releasing VEGF and promoting 
angiogenesis (Ricci-Vitiani L et al., 2011). Thus, inhibition of tumor angiogenesis may 
especially target the cancer stem cell population with the hope of achieving more durable 
clinical responses. (Folkins, 2007) Antiangiogenic therapy that targets VEGF signaling has 
evolved into an important therapeutic treatment strategy. Bevacizumab (Avastin®) is a 
humanized anti-VEGF antibody that demonstrates promising results in treating patients 
with glioblastomas and have been approved by the United States FDA for the treatment of 
recurrent of progressive GBMs (Vredenburgh et al., 2007; Huang Z et al., 2010). In a 
retrospective study of 55 patients with GBM done by Norden et al., the result showed a 
promising data where the median 6-month progression survival rates were 42% (Brastianos 
& Batchelor, 2010; Norden AD et al., 2008). Similar promising results have also been 
reported in other subsequent studies in randomized phase II trials where the patients in the 
bevacizumab arm showed 42% 6-month progression survival (Therasse P et al., 2000). 
Aflibercept (Regeneron®) is a potent, VEGF-trap that is fused to an immunoglobulin 
constant region. In a study done by De Groot et al., aflibercept brought therapeutic response 
to 30% of GBM patients. Future trials examining aflibercept in treating malignant gliomas is 
still underway (De Groot JF et al., 2008).  
There are range of novel RTK inhibitors, such as cediranib, vandetanib, vatalanib, sorafenib, 
sunitinib, pazopanib, AE-788, and CT-322 that have been shown to influence angiogenesis 
and tumor growth through multiple targets and are currently in various stages of preclinical 
and clinical investigation. (Brastianos & Batchelor, 2010). Cediranib (Recentin®) is a potent 
pan-VEGFR, PDGFR and c-KIT inhibitor that showed objective response in 57% of the 
patients in a phase II trial (Batchelor TT et al., 2007). Vandetanib (Zactima®) is a selective 
inhibitor of VEGFR2 and EGFR and showed promising antiglioma effects in preclinical 
studies (Rich JN et al., 2005). Vatalanib is a an oral pan-VEGFR, PDGFR, c-Kit inhibitor that 
reduced the activity of VEGF-mediated glioma growth (Goldbrunner et al., 2004). In a phase 
I/II trial, vatalanib produced radiographic responses in 4% of the patients and resulted in 
stable disease response rate of 56% (Conrad C et al., 2004). Sorafenib (Nexavar®) is a multi-
target inhibitor that targets VEGFR, PDGFR, c-KIT, and Raf. It is approved to be used in a 
single-agent, monotherapy setting and data from phase I trial indicates that patients well 
tolerated the drug (Jane EP et al., 2006; Nabors L et al., 2007). Sunitinib (Sutent®) is also a 
multi-target kinase inhibitor that displayed promising and efficacious antiangiogenic 
activity and antitumor activity in GBM models in vitro and in vivo. Pazopanib (Voltrient®) is 
another multi-target kinase inhibitor of VEGFR-1, -2, and -3, PDGFR and c-KIT and in a 
recent phase II study, pazopanib was well tolerated with median progression-free survival 
being 12 weeks (Iwamoto FM et al., 2010). Studies exploring the therapeutic efficaciousness 
of AE-788 and CT-322 are underway, which are oral inhibitor of EGFR, HER2 and VEGFR2 
and pegylated protein inhibiting VEGFR-2 signaling pathway cascade, respectively 
(Brastianos & Batchelor, 2010). 
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Exploring VEGF signaling pathway is crucial in treating malignant glioma because these 
anti-VEGF agents can normalize the blood vessels, which will allow to improve the delivery 
of chemotherapy agents that will produce favorable radiation response. Even though there 
are many promising data published regarding the therapeutic efficacy of VEGF inhibitors in 
pre-clinical and clinical settings, more studies are in development to confirm these results 
and to understand the complexity of molecular signaling pathways.  
 
 
Fig. 2. Signaling pathways important for stem cell signaling 
Pharmacological interference with these pathways promises to have therapeutic potential in 
targeting cancer stem cells. Receptor tyrosine kinase-mediated signaling (FGF, PDGF, EGF, 
VEGF) promotes progenitor cell proliferation and angiogenesis. PTEN acts as a tumor-
suppressor gene and is frequently inactivated in gliomas. The 
Wnt/b-catenin pathway leads to accumulation of intranuclear b-catenin and transcription of 
target genes critical for stem cell and progenitor cell function. Shh binds to its associated 
transmembrane receptor PTC1, releasing the membrane protein Smo, which results in 
downstream activation of the Gli proteins and transcription factors. Bmi1 controls 
maintenance of stem cells by repressing genes that promote differentiation or cell death, 
such as the tumor suppressors p16Ink4a and p19Arf. Binding of the cell membrane-
associated Notch receptor proteins and their associated ligands (not shown) leads to 
cleaving of the intracellular domain of Notch (NICD) and transcription of target genes 
essential for maintenance and self-renewal of stem cells. PTC1: Patched 1; Shh: Sonic 
hedgehog; Smo: Smoothened. 
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Fig. 3. Major signaling pathways in malignant gliomas and the corresponding targeted 
agents in development for glioblastoma 
RTK inhibitors that target epidermal growth factor (EGF) receptor include gefitinib, 
erlotinib, lapatinib, BIBW2992, and vandetanib; those that target plateletderived growth 
factor (PDGF) receptor include imatinib, dasatinib, and tandutinib; those that target vascular 
endothelial growth factor (VEGF) receptor include cediranib, pazopanib, sorafenib, unitinib, 
vatalanib, vandetanib, and XL184. EGF receptor antibodies include cetuximab and 
anitumumab. Farnesyl transferase inhibitors include lonafarnib and tipifarnib; HDAC 
inhibitors include depsipeptide, vorinostat, and LBH589; PI3K inhibitors include BEZ235 
and XL765; mTOR inhibitors include sirolimus, temsirolimus, everolimus, and deforolimus; 
and VEGF receptor inhibitors include bevacizumab, aflibercept (VEGF-trap), and CT-322. 
Growth factor ligands include EGF, PDGF, IGF, TGF, HGF/SF, VEGF, and FGF. Stem-cell 
pathways include SHH, wingless family, and Notch. Akt denotes murine thymoma viral 
oncogene homologue (also known as protein kinase B), CDK cyclin-dependent kinase, ERK 
extracellular signal-regulated kinase, FGF fibroblast growth factor, FTI farnesyl transferase 
inhibitors, GDP guanine diphosphate, Grb 2 growth factor receptor-bound protein 2, GTP 
guanine triphosphate, HDAC histone deacetylase, HGF/SF hepatocyte growth 
factor/scatter factor, IGF insulin-like growth factor, MEK mitogen-activated protein kinase 
kinase, mTOR mammalian target of rapamycin, NF1 neurofibromin 1, PIP2 
phosphatidylinositol (4,5) biphosphate, PIP3 phosphatidylinositol 3,4,5-triphosphate, PI3K 
phosphatidylinositol 3-kinase, PKC protein kinase C, PLC phospholipase C, PTEN 
phosphatase and tensin homologue, RAF v-raf 1 murine leukemia viral oncogene 
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homologue 1, RAS rat sarcoma viral oncogene homologue, RTK receptor tyrosine kinase 
inhibitor, SHH sonic hedgehog, SOS son of sevenless, Src sarcoma (Schmidt-Ruppin A-2) 
viral oncogene homologue, TGF transforming growth factor family, and TSC1 and 2 
tuberous sclerosis gene 1 and 2. Red text denotes inhibitors. 
3.4 RAS/Raf/MAPK & AKT/PI3K pathways 
Downstream effects of RTK signaling include activation of Ras/ Raf/MAPK and 
AKT/PI3K, promoting cell survival, cell proliferation, cell migration and angiogenesis. 
Malignant gliomas and glioblastomas have hyperactivated phosphatidylinositol-3-kinase 
(PI3K)-Akt , also known as protein kinase B) pathway that serve as the genesis of human 
cancers (Eyler C et al., 2008; Castellino RC et al., 2007; Wlodarski P et al., 2006; Knobbe CB et 
al., 2005). Once Akt signaling pathway is hyperactivated it results in the proliferation, 
invasion, and angiogenesis of tumor cells. AKT/PI3K activation through loss of PTEN in 
combination with constitutively active EGFR signaling has been shown to induce glial 
tumor formation along with genetic instability in experimental models (Eyler C et al., 2008). 
Interestingly, glioma stem cells appear to be more dependent on AKT signaling than non-
stem glioma cells, suggesting that AKT inhibition is crucial in managing the tumor stem 
cells from expanding and treating brain tumors more effectively (Eyler C et al., 2008). 
Currently, there are various clinical trials observing tem- sirolimus (CCI-779), its active 
metabolite sirolimus (rapamycin), everolimus (certican), and AP23573, which are mTOR 
inhibitors that target PI3K signaling pathway (Galanis,2005; Chang,2005; Kuhn,2007). 
3.5 Sonic hedgehog signaling 
Sonic hedgehog (Shh) is a key regulator and a determinant that is crucial for the generation 
and maintenance of adult stem cells (Dave R et al., 2011). Hedgehog (Hh) signaling is also 
involved in patterning, growth, and cell fate determination in many developing organ 
systems. Upon secretion, the hedgehog molecules bind to Patched 1 protein (PTCH1) and 
inhibit the receptor. Once inactivated, PTCH1 accumulates Smoothened (SMOH) in its 
cytoplasm instead of releasing them (Dave R et al., 2011). These results in downstream 
activation of the Gli proteins – zinc-finger transcription factors that translocate to the 
nucleus and may either activate or repress downstream targets, such as Wnt, IGF and 
PDGFR-a, myc and cyclin D1. Shh is important in regulating neural stem cells, neural tube 
patterning, and neurogenesis (Machold, 2003; Park, 2003; Lai, 2003; Palma, 2005; Cai, 2008; 
Han, 2008; Komada, 2008). Recent studies show that SHH-neutralizing antibodies help in 
inhibiting tumor cell growth and reducing its proliferation rates (Chen YJ et al., 2007; Thayer 
SP et al., 2003; Berman DM et al., 2003; Karhadkar SS et al., 2004). Early clinical trials (e.g., 
GDC-0449) are ongoing to evaluate inhibitors of Shh signaling (Rudin,2009). Collectively, 
Shh-mediated signaling is critically important in stem cell and tumor biology and may 
constitute another attractive target for therapy of malignant brain tumors. 
3.6 PTEN 
Phosphatase and tensin (PTEN) homologue gene has important functions in both normal 
neural stem cell physiology and oncogenic processes. It acts mainly as a tumor suppressor 
gene and is involved in many cellular functions including cell cyle progression, 
angiogenesis, migration, invasions, and stem cell regulation (Cheng RB et al., 2010; Alexiou 
GA et al., 2010). However, in many malignant gliomas, PTEN genes are often deleted or 
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mutated, which contributes to the pathologic progression of the tumor cells. This loss of 
PTEN leads to constitutive activation of AKT and resistance to apoptosis (Maehama T et al., 
1998; Radu A et al., 2003; Stiles B et al., 2002). In turn, this down-regulation of PTEN results 
in aggressive tumor expansion and poor prognosis. PTEN inactivation in combination with 
EGFR amplification is sufficient to cause invasive gliomas in experimental mouse models, 
supporting the critical role of PTEN inactivation in gliomagenesis. Furthermore, it has been 
suggested that loss of PTEN enhances resistance to EGF RTK inhibitors in glioblastoma 
patients (Mellinghoff, 2007). 
4. Targeted molecular therapy 
In recent years, there has been tremendously increased understanding of the molecular 
abnormalities occurring in malignant gliomas (Maher,et al.,2001; Kitange,et al.,2003; 
Konopka&Bonni,2003). Molecular analysis of gliomas shows a step-wise progression of 
genetic changes involving overexpression of proto-oncogenes and loss of tumor suppressor 
genes. Low-grade astrocytomas (World Health Organization [WHO] grade II) tend to have 
inactivating mutations of TP53 and overexpression of platelet-derived growth factor (PDGF) 
and their receptors (PDGFR). Progression to anaplastic astrocytomas (WHO grade III) is 
associated with inactivation of the p16-cdk4-Rb pathway and allelic loss of 19q, whereas 
progression further to a secondary glioblastoma (WHO grade IV) is associated with loss of 
chromosome 10 and other changes. Primary glioblastomas, which originate de novo, often 
have loss of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), 
together with amplification, mutation, and overexpression of the epidermal growth factor 
receptors (EGFR). There is increasing work on molecular profiling of malignant gliomas 
using a variety of different techniques.  
These approaches are beginning to enable genes that are important in tumor progression to 
be identified (van den Boom et al., 2003). In addition, morphologically indistinguishable 
malignant gliomas can be differentiated into molecular subtypes that may eventually be 
used for identifying potential targets for treatment (Mischel et al., 2003; Rao et al., 2003), for 
patient stratification in clinical studies (Shai et al., 2003), and for determining prognosis 
(Nutt et al., 2003). 
Recently, inhibitors of oncogenes and signaling pathways have shown promising 
therapeutic potential in the treatment of several systemic cancers (Drucker, 2002). The 
prototypic targeted molecular agent is imatinib mesylate (Gleevec; Novartis, Basel, 
Switzerland), a small molecule inhibitor of the abl, c-kit, and PDFGR tyrosine kinases. It has 
demonstrated significant antitumor activity in chronic myelogenous leukemia (CML) by 
inhibiting the abl tyrosine kinase and in gastrointestinal stromal tumors (GIST) by inhibiting 
c-kit (Drucker, 2002). The success of imatinib in these tumors demonstrates the potential of 
these agents in tumors with well defined molecular targets. Although the complexity of the 
molecular abnormalities in malignant gliomas and the redundancy of the signaling 
pathways make it unlikely that single agents will achieve the same success as imatinib in 
CML, there has been significant interest in this approach (Karpati et al., 2003; Newton, 2004; 
Mischel, 2003). Over the past years, several of the first generation trials evaluating targeted 
molecular agents in malignant gliomas have reached maturity, and it is possible to draw 
some preliminary conclusions. In general, these agents have been well tolerated, but 
unfortunately only small subsets of patients have benefited. 
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Table 1. Selected small-molecule inhibitors with activity against signaling pathways relevant 
to cancer stem cells in malignant gliomas 
5. Conclusion 
The discovery that malignant tumors contain small subpopulations of cells that are highly 
tumorigenic and share features with normal stem cells has stimulated the field of cancer 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
282 
research and established a novel concept in tumor biology – that most cancers, including 
glioblastomas, are driven by  ‘cancer stem cells’ responsible for tumorigenesis and resistance 
to conventional therapies. Understanding the mechanisms and signaling pathways that 
govern cancer stem cells will be a key to identifying effective therapies to eventually 
improve tumor control and clinical outcome. A number of problems will have to be 
overcome in the development of effective therapies targeting cancer stem cells. Cancer stem 
cells are typically slowly cycling cells, express high-levels of drug-resistance genes and may 
not necessarily depend on oncogenes and their gene products targeted by small-molecule 
inhibitors. Further progress in glioma research will come from the molecular profiling of 
well-characterized cancer cell populations (e.g., after FACS analysis) and the identification 
of novel cellular markers that will provide the foundation to track cancer stem cells in vitro 
and in vivo. There is significant need to improve our ability to monitor treatment response 
with novel biomarkers so that patients who are resistant to therapy may be identified early 
in the treatment course. Moreover, novel biomarkers or surrogate markers of activity, and 
advances in molecular imaging in combination with tumor tissue analysis from patients 
enrolled into clinical trials will be important to evaluate treatment response and to 
understand treatment failure.  
Several signaling pathways that orchestrate normal neural stem and progenitor cells are 
adopted by cancer stem cells and drive tumor cell proliferation, migration and treatment 
resistance. 
Further elucidation of the molecular circuitry driving tumorigenesis and treatment 
resistance will be essential to advance our knowledge in glioma biology and to translate 
these concepts into the clinical arena. Both targeting the cancer stem cell compartment and 
individualizing patient treatment based on the unique signaling features in a given tumor 
have the greatest potential to translate into a successful treatment strategy. 
While the first generation of molecular targeted therapies have shown promising results in 
preclinical studies, most agents have failed to translate into significant clinical benefit in 
early clinical trials. Preliminary clinical studies suggest that inhibition of a single pathway 
may not be sufficient to inhibit glioma growth in order to prolong patient survival (Pillay, et 
al., 2009). Therefore, targeting multiple pathways and signaling components in combined 
treatment approaches promises to be more successful. 
However, given the increasing number of putative targets and agents, and the exponentially 
increasing number of potential combinations used in patients, it will be important to 
identify the most promising combinations and to carefully design and plan clinical trials. 
Recent genomic studies highlight the fact that gliomas are heterogeneous tumors. 
(Parsons,et al.,2008) Consequently, it will be important to integrate information derived 
from large genomic studies and combine it with our increasing understanding of 
mechanisms relevant to cancer stem cells in order to effectively treat brain tumor patients. 
With recent efforts to individualize cancer treatment in patients, molecular targeted 
therapies directed to cancer stem cells and their signaling pathways will be increasingly 
used in the near future by clinicians and oncologists. An important issue of concern has 
come from recent studies on the cell-biological analysis of cancer therapy-associated 
neurotoxicity. Both radiation and cytotoxic therapies have been shown to be highly toxic to 
neural progenitor cell populations important for the maintenance of normal brain function, 
and may disrupt neurogenesis and white matter integrity (Dietrich, et al., 2006; Han, et al., 
2008; Monje, 2002; Dietrich, et al., 2008). As multiple new molecular agents have been 
developed to specifically target signaling pathways employed by normal neural stem and 
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progenitor cells, serious neurotoxic adverse effects may be encountered in long-term 
survivors. Another concern has come from recent experimental studies demonstrating that 
molecular targeted therapies with antiangiogenic compounds may promote tumor cell 
migration and metastasis (Holash et al., 1999; Rubenstein et al., 2000; Loges et al., 2009; Ebos 
et al., 2009; Paez-Ribes et al., 2009). 
Regardless, targeted molecular therapies hold great promise and will become an important 
component of combined treatment approaches in our effort to fight cancer. 
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